EMA/34364/2021 Corr

European Medicines Agency decision

P/0037/2021

of 27 January 2021

on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (Reblozyl), (EMEA-001521-PIP01-13-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0037/2021

of 27 January 2021

on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (Reblozyl), (EMEA-001521-PIP01-13-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0245/2014 issued on 29 September 2014, the decision P/0219/2017 issued on 9 August 2017, the decision P/0122/2018 issued on 11 April 2018, the decision P/0130/2019 issued on 17 April 2019, and the decision P/0024/2020 issued on 6 January 2020,

Having regard to the application submitted by Celgene Europe B.V. on 10 September 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 December 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and to the waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral and to the waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for luspatercept (Reblozyl), powder for solution for injection, subcutaneous use, including changes to the deferral and to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Celgene Europe B.V., Winthontlaan 6 N, 3526 KV - Utrecht, The Netherlands.

EMA/PDCO/517209/2020 Corr
Amsterdam, 11 December 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001521-PIP01-13-M05

Scope of the application

Active substance(s):

Luspatercept

Invented name:

Reblozyl

Condition(s):

Treatment of myelodysplastic syndromes

Treatment of beta-thalassaemia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Celgene Europe B.V.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Celgene Europe B.V. submitted to the European Medicines Agency on 10 September 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0245/2014 issued on 29 September 2014, the decision P/0219/2017 issued on 9 August 2017, the decision P/0122/2018 issued on 11 April 2018, the decision P/0130/2019 issued on 17 April 2019, and the decision P/0024/2020 issued on 6 January 2020.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and to the waiver.

The procedure started on 13 October 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral and to the waiver.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of myelodysplastic syndromes

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- powder for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

1.2. Condition

Treatment of beta-thalassaemia

The waiver applies to:

- the paediatric population from birth to less than 6 years;
- powder for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Treatment of beta-thalassaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of anaemia in patients with beta-thalassaemia intermedia and major

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate self-administration device for subcutaneous use, allowing sufficient accuracy of dose measurement and delivery in all age groups to be treated
Non-clinical studies	2	**Study 2 (1383657025333)** Dose range-finding juvenile toxicity study **Study 3 (1381154982795)** Definitive juvenile toxicity study
Clinical studies	3	**Study 4** Study to evaluate safety and pharmacokinetics of luspatercept in paediatric patients from 6 years to less than 18 years of age with transfusion-dependent beta-thalassaemia **Study 5 (1406216840211)** Two-part, double-blind, randomised, placebo controlled trial to evaluate pharmacokinetics, safety and efficacy of luspatercept in children from 6 years to less than 18 years of age with non-transfusion-dependent beta-thalassaemia **Study 6** Double-blind, randomised, placebo controlled trial to evaluate safety and efficacy of luspatercept in paediatric patients from 6 years to less than 12 years of age with transfusion-dependent beta-thalassaemia
Extrapolation, modelling and simulation studies	2	**Study 7** *(added in procedure EMEA-001521-PIP01-13-M05)* Modelling and simulation study to describe luspatercept serum exposure data and factors associated with the exposure variability in children from 12 to less than 18 years of age (and adults) with beta thalassaemia **Study 8** *(added in procedure EMEA-001521-PIP01-13-M05)* Study of existing and emerging exposure-response data of luspatercept to support efficacy extrapolation from adults to children from 12 to less than 18 years of age with beta thalassaemia
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2033
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of myelodysplastic syndromes

Authorised indication(s):

- Treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy

2. Treatment of beta-thalassaemia

Authorised indication(s):

- treatment of adult patients with transfusion-dependent anaemia associated with Beta-thalassaemia

Authorised pharmaceutical form(s):

Powder for solution for injection

Authorised route(s) of administration:

Subcutaneous use